Aminoterminal pro-brain natriuretic peptide (NT-proBNP) and sleep-disordered breathing in morbidly obese females: a cross-sectional study

Abstract

Sleep-disordered breathing (SDB) is often encountered in morbid obesity (MO) in conjunction with insulin resistance (IR). Aminoterminal pro-brain natriuretic peptide (NT-proBNP) is a promising marker for left ventricular dysfunction (LVD) in MO. We sought to explore the factors that may influence the relationships of SDB and IR with NT-proBNP in MO women.

We performed a cross-sectional pilot study involving 110 asymptomatic MO (44.5±0.7 kg/m²) young women. SDB risk was assessed using a modified version of the Berlin Questionnaire (BQ). IR was assessed using the homeostasis model assessment (HOMA) index and adiponectin levels. LVD was assessed using NT-proBNP and echocardiograms.

In this study, NT-proBNP levels and LVD increased significantly along the BQ strata. Multiple regression analysis identified BQ and log-transformed HOMA as the independent variables predicting as much as 48.0% of the variability of logNT-proBNP.

In conclusion, NT-pro-BNP levels are independently predicted by SDB and IR in asymptomatic MO women. Larger prospective studies are warranted.

Keywords

Berlin Questionnaire diastolic dysfunction HOMA index morbid obesity NT-proBNP

References

1. Allison DB , Fontaine KR , Manson JE , Stevens J , Vanltallie TB . Annual deaths attributable to obesity in the United States. JAMA 1999;282:1530–8.

2. World Health Organization . Obesity: preventing and managing the global epidemic. World Health Organization: Geneva, Switzerland, 1998.

3. Fritscher LG , Dixon JB , Mottin C , Cananis S , Chatkin JM . Obesity and obstructive sleep apnea-hypopnea syndrome: the impact of bariatric surgery. Obes Surg 2007;17:95–9.

4. Strollo PJ Jr , Rogers RM . Obstructive sleep apnea. N Engl J Med 1996;334:99–104.

5. Young T , Palta M , Dempsey J , Skatrud J , Weber S , Badr S . The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230–5.

6. Tasali E , Van Cauter E . Sleep-disordered breathing and the current epidemic of obesity: consequence or contributing factor? Am J Respir Crit Care Med 2002;165:562–3.

7. Ingelsson E , Sundstrom J , Arnlov J , Zethelius B , Lindl L . Insulin resistance and risk of congestive heart failure. JAMA 2005;294:334–41.

8. Kopelman PG . Obesity as a medical problem. Nature 2000;404:635–43.

9. Avelar E , Cloward TV , Walker JM et al. Left ventricular hypertrophy in severe obesity: interactions among blood pressure, nocturnal hypoxemia, and body mass. Hypertension 2007;49:34–9.

10.

10. Evrengul H , Dursunoglu D , Kaftan A , Klicaslan F , Tanriverdi H , Klic M . Relation of insulin resistance and left ventricular function and structure in non-diabetic patients with essential hypertension. Acta Cardiol 2005;60:191–8.

11.

11. Wilcox I , McNamara SG , Collins FL , Grunstein RR , Sullivan CE . “Syndrome Z”: the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax 1998;53(suppl 3):S25–S28.

12.

12. Melanson SE , Lewandrowski EL . Laboratory testing for B-type natriuretic peptides (BNP and NT-proBNP): clinical usefulness, utilization, and impact on hospital operations. Am J Clin Pathol 2005;124(suppl): S122–S128.

13.

13. Costello-Boerrigter LC , Boerrigter G et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345–53.

14.

14. Anwaruddin S , Lloyd-Jones DM , Baggish A et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47:91–7.

15.

15. Morricone L , Malavazos AE , Coman C , Donati C , Hassan T , Caviezel F . Echocardiographic abnormalities in normotensive obese patients: relationship with visceral fat. Obes Res 2002;10:489–97.

16.

16. Mehra MR , Uber PA , Park MH et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590–5.

17.

17. Kistorp C , Faber J , Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756–62.

18.

18. Bayes-Genis A , Lloyd-Jones DM , van Kimmenade RR et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007;167:400–07.

19.

19. Das SR , Drazner MH , Dries DL et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005;112:2163–8.

20.

20. Van Kimmenade R , van Dielen F , Bakker J et al. Is brain natriuretic peptide production decreased in obese subjects? J Am Coll Cardiol 2006;47:886–7.

21.

21. Netzer NC , Stoohs RA , Netzer CM , Clark K , Strohl KP . Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999;131:485–91.

22.

22. Tasali E , Van Cauter E , Ehrmann DA . Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:36–42.

23.

23. Alam M , Wardell J , Anderson E , Samad BA , Nordlander R . Characteristics of mitral and tricuspid annular velocities determined by pulsed wave Doppler tissue imaging in healthy subjects. J Am Soc Echocardiogr 1999;12:618–28.

24.

24. Devereux RB , Reiche N . Echocardiographic determination of left ventricular mass in man. Anatomic evaluation of the method. Circulation 1977;55:613–18.

25.

25. Levy D , Savage DD , Garrison RJ , Anderson KM , Kannel WB , Castelli WP . Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 1987;59:956–60.

26.

26. Matthews DR , Hosker JP , Rudenski AS , Naylor BA , Treacher DF , Turner RL . Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412–19.

27.

27. Karl J , Borgya A , Gallusser A et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999;230:177–81.

28.

28. Nieto FJ , Young TB , Lind BK et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829–36.

29.

29. Peppard PE , Young T , Palta M , Skatrud J . Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378–84.

30.

30. Fogel RB , Malhotra A , Pillar G , Pittman SD , Dunaif A , White DP . Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:1175–80.

31.

31. Gopal M , Duntley S , Uhles M , Attarian H . The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med 2002;3:401–04.

32.

32. Svatikova A , Wolk R , Gami AS , Pohanka M , Somers VK . Interactions between obstructive sleep apnea and the metabolic syndrome. Curr Diab Rep 2005;5:53–8.

33.

33. Vgontzas AN , Papanicolaou DA , Bixler EO et al. Sleep apnea and day-time sleepiness and fatigue relation to visceral obesity, insulin resistance and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151–8.

34.

34. Punjabi NM , Sorkin JD , Katzel LI , Goldberg AP , Schwartz AR , Smith PL . Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002;165:677–82.

35.

35. Vgontzas AN , Legro R , Bixler EO , Grayev A , Kales A , Chrousos GP . Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001;86:517–20.

36.

36. Ip S , Lam B , Ng M , Lam W , Tsang K , Lam K . Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002;165:670–6.

37.

37. Ferrannini E , Balkau B . Insulin: in search of a syndrome. Diabet Med 2002;19:724–9.

38.

38. Olsen MH , Hansen TW , Christensen MK et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005;46:660–6.

39.

39. McCord J , Mundy BJ , Hudson MP et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004;164:2247–52.

40.

40. Wang TJ , Larson MG , Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004;109:594–600.

41.

41. St Peter JV , Hartley GG , Murakami MM , Apple FS . B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. Clin Chem 2006;52:680–5.

42.

42. Dessi-Fulgheri P , Sarzani R , Rappelli A . The natriuretic peptide system in obesity-related hypertension: new pathophysiological aspects. J Nephrol 1998;11:296–9.

43.

43. Minami J , Nishikimi T , Matsuoka H . Plasma brain natriuretic peptide and N-terminal proatrial natriuretic peptide level in obese patients: a cause or result of hypertension [letter]? Circulation 2004;110:e76.

44.

44. Vgontzas AN , Tan TL , Bixler EO , Martin LF , Shubert D , Kales A . Sleep apnea and sleep disruption in obese patients. Arch Intern Med 1994;154:1705–11.

45.

45. Bearpark H , Elliott L , Grunstein R et al. Snoring and sleep apnea: a population study in Australian men. Am J Respir Crit Care Med 1995;151:1459–65.

46.

46. Malavazos AE , Morricone L , Marocchi A , Ermetici F , Ambrosi B , Corsi MM . N-terminal pro-B-type natriuretic peptide and echocardiographic abnormalities in severely obese patients: correlation with visceral fat. Clin Chem 2006;52:1211–13.

47.

47. Hermann-Arnhof KM , Hanusch-Enserer U , Kaestenbauer T et al. N-terminal pro-B-type natriuretic peptide as an indicator of possible cardiovascular disease in severely obese individuals: comparison with patients in different stages of heart failure. Clin Chem 2005;51:138–43.